The company was founded by several senior scientists who worked in the United States and returned to China full-time. It is committed to the research and development, production, clinical trials and marketing of monoclonal antibody-drug conjugate (ADC) biologics targeting advanced cancers.
Each founding scientist has more than 20 years of experience in innovative drug research and development. They are very knowledgeable and possess unique insights, superb skills and continuous innovation capabilities in the ADC field. The professional backgrounds of the company’s key technical teams cover medicinal chemistry, molecular biology, cell biology, organic chemistry, antibody engineering, biochemistry, analytical chemistry, pharmacology and pharmacokinetics, production processes, quality control and quality management, clinical Medicine, and other relevant drug development and production fields.
After nine years of research and development, DAC Biotechnology has established a special ADC technology platform, with 30 ADC drugs in different development stages, and has become a leader in the ADC field. Our ADC platform with independent intellectual property rights which includes: at least 50 new intelligent linkers (including site-specific coupling); more than 100 of small molecule cytotoxins which by mechanisms of action belong to five categories such as Tubulysin, DNA small groove binder (PBD), DNA alkylation (Duocarmycin), RNA polymerase inhibitors (Amanitin), topozyme inhibitors (CPT), etc.; antibody generation, engineering and production process development;. in vivo and in vitro ADC functional evaluation; drug structure analysis and confirmation; analytical method development and verification systems required for quality control, and so on.
The company has 31 PCT patents in the ADC field. As of December 31, 2023, the company has submitted more than 500 patent applications in more than 21 countries and regions (including China, the United States, the European Union, Japan, Canada, Australia, New Zealand, South Korea, Brazil, South Korea, Africa, India, Singapore, Vietnam, Mexico, Taiwan, Hong Kong, Indonesia, Malaysia, the Philippines, Chile, Israel, Egypt, Thailand, Russia and Central Asia, etc.), of which 21 patents have been authorized in the United States alone.
In the past nine years, the company has invested more than 300 million CYN in R&D and clinical studies it is equip with a large number of advanced R&D, inspection and pilot production instruments and facilities and a multi-functional R&D and pilot test platform is established. which includes high-activity small molecule cytotoxin design, synthesis, evaluation, pilot production and test; antibody generation and functional validation; antibody production cell line establishment, optimized antibody expression and pilot production; ADC drug conjugation, analysis and testing; rodent level ADC efficacy and toxicology evaluation, pharmacokinetic analysis and product QC/QA , etc.
With the strong support of our investors, DAC Biotechnology has been growing solidly and steadily.
We are confident that aimed at the discovery, development, clinical research and commercialization of a series of novel ADC drugs, Hangzhou DAC Biotechnology will write its own unique and magnificent chapter in the history of human struggle with cancer.